Biogen Inc. and Eisai Co. Ltd. are abandoning two late-stage trials for their Alzheimer’s treatment elenbecestat in a widely anticipated move that comes months after the companies scrapped studies of aducanumab for the memory-robbing disease.
Shares of Acadia Pharmaceuticals were up nearly 70 percent after a Phase III psychosis trial was halted early as the Parkinson’s disease drug Nuplazid hit primary endpoints, positioning the company to seek another potential regulatory approval.
Seven Scoops ice cream shop in Pine Brook, New Jersey, is donating every penny of ice cream sales on Aug. 26th to support ALS Ice Bucket Challenge Co-Founder Pat Quinn.
Biogen Inc. reported better-than-expected second quarter 2019 profit and raised the company’s full-year earnings forecast, driven by higher sales of the top-selling multiple sclerosis drug Tecfidera and lower taxes.
Biohaven Pharmaceutical Holding Co. Ltd. said the U.S. health regulator failed to approve the company’s treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.
The U.S. Food and Drug Administration approved Zolgensma, a gene therapy that Novartis called a life-changing medicine, for children younger than 2 years of age who have been diagnosed with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 gene.
Cytokinetics’ ALS Treatment Fails to Hit Endpoints in Phase II, Company Notes Several Positive Results
Shares of Cytokinetics Inc. were down more than 15 percent after the company announced that the experimental amyotrophic lateral sclerosis treatment reldesemtiv failed to hit endpoints in a Phase II trial.
San Diego-based Neurocrine Biosciences presented data from two Phase III clinical trials of opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease.
Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.
Novartis AG won U.S. Food and Drug Administration approval for the multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition.